DOCSLIB.ORG

For TOR – Expansion Case

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For TOR – Expansion Case SEAC, Gujarat: Page 1 of 10 For TOR – Expansion Case 1. Basic Information of the Project: i Name & Address of the Project site (Complete M/s. Stermone Chemicals Pvt. Ltd., details with plot no./Survey no., Landmark etc. ) Plot No. 34/01, Paldi, Golana Road, Taluka: Khambhat, Dist.Anand ii Name of the Applicant Mr. Premchand S. Patil iii Address for correspondence Plot No. 34/01, Paldi, Golana Road, Taluka: Khambhat, Dist. Anand iv Contact no. and e-mail ID of the Applicant [email protected] Cell No:- +91-9727877450 v Aerial distance of nearest Habitat (KM) Khambhat : 6.40 km vi Longitude & Latitude of the Project Site: (4 Project Site: corners of the site) 1) 22˚ 21’ 40 .38” N 72˚ 35’ 02 .10” E 2) 22˚ 21’ 39 .40” N 72˚ 35’ 06 .30” E 3) 22˚ 21’ 41 .69” N 72˚ 35’ 09 .21” E 4) 22˚ 21’ 43 .69” N 72˚ 35’ 04 .62” E vii Category as per the Schedule to the EIA 5(f) , “Category B” Notification 2006 i.e. 1(d), 2(b), 5(f) etc. viii Applicability of General Conditions of EIA -- Notification 2006: i.e. Ensure that I. Protected areas notified under the Wildlife (Protection) Act, 1972; II. CEPI areas III. Eco-sensitive areas and IV. Inter-state boundaries and international boundaries; are not located within 5 km or 10 km (as the case may be) area from the boundary of the proposed site. 2. Online application proposal no. : _______ 3. Date of application for TOR: 14/02/2018 4. Project status: Expansion 5. Product profile: As per Annexure-I The project falls under Category B of project activity 5(f) as per the schedule of EIA Notification 2006. 6. Product wise Raw material consumption: As per prefeasibility report 7. Compliance status of the existing project: Sr. Particulars Brief Information/Details Remarks no. 1 Earlier EC details F.No.J-11011/11/2008-IA II (I) -- Dated 10th September,2009 2 Compliance of EC We have regularly submit half yearly -- compliance report to concern authority 3 Status of inspection by RO- No visit from RO MOEF till date -- SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 2 of 10 MoEFCC, Bhopal. 4 Status of submission of half -- yearly return to concern Last submitted for Dec 2017 authorities. 5 Compliance of existing CC&A Complied -- 6 Legal actions/Closure -- There is no legal Notices Issued by directions/SCN etc. issued GPCB by GPCB. 7 Any Public Complaints No public complaints -- 8 Is there any litigation pending -- There is no litigation pending against before any court of Law the project against the Project? 8. Salient Features of the project including Water, Air and Hazardous waste Management: Sr. Particulars Details no. A Total cost of Proposed Project Existing: Rs.1.84 (Rs. in Crores): Proposed: Rs.3.78 Crore approx Total: Rs. 5.62, Crore approx (1) Capital cost for EMS (Environmental Management System): Rs. 3 Crores (2) Recurring cost towards the environmental protection measures: 1.8 Crores per Annum. B Total Plot area Existing: 14404 sq. m. ( sq. meter) Proposed: NIL Total: 14404 sq. m. Green belt area,/Tree Plantation area Existing: 4754 sq. m. ( sq. meter) Proposed: 0 sq. m. Total: 4754 sq. m. C Employment generation 1. Staff Existing: 18 Proposed: 20 Total: 38 2. Labour Existing: 25 Proposed: 25 Total: 50 D Water i Source of Water Supply GWSSB water supply (GIDC, Bore well, Surface water etc.) Status of permission from the concern authority. ii Water consumption (KL/day) - Proposed Total after Existing Category (Additional) Expansion Remarks KL/day KL/day KL/day (A) Domestic 0.25 4.75 5 -- (B) Gardening 0.90 2.1 3 -- (C) Industrial Process 0.90 15.1 14+2 -- Boiler 0.20 11.8 1+11 -- Cooling 0.20 1.8 2 -- SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 3 of 10 Washing 0.10 2.9 3 -- Scrubber 0 1 1 -- Total (A+B+C) 23 19 KL recycled water also used - iii Waste water generation (KL/day) - Proposed Total after Existing Category (Additional) Expansion Remarks KL/Day KL/day KL/day (A) Domestic 0.2 2.8 3 -- Industrial Process 0.41 14.59 15 -- Boiler 0.02 1.98 2 -- Cooling 0.02 0.48 0.5 -- Washing 0.10 2.9 3 -- Scrubber 0 0 0 -- Total Industrial waste 0.75 23.75 24.5 -- water - iv Treatment facility with capacity ETP 25 KLD (ETP, CETP, MEE, STP etc). MEE 20 KL:D Incinerator 2 KLD v Mode of Disposal & Final meeting point Domestic: Soak Pit Industrial: ETP,MEE vi Reuse/Recycle details (KL/day) 19 KLD E Air (Existing and Proposed) i Flue gas emission details No. of Boilers/TFH/Furnaces/DG sets etc. with capacities viz. TPH, Kcal/hr, MT/hr, KVA etc. - Source NAAQS of (National emissi Stack Type of Ambient S on Quantity emissi Air R. Heigh Name of the of Fuel ons i.e. APCM Quality no With t fuel MT/hr & Air Standar . Capaci (mete MT/Day Polluta ds) ty e.g. r) nts Boiler (8 TPH) Cyclone PM 150 Flue 3 1 Boiler 13 Agro Waste Separat mg/Nm 100 kg/Hr gas /Briquette Sox 100 stack or SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 4 of 10 D.G. ppm Set No 150 Flue x 2 (Stand 11 Diesel - ppm 20 Lit/Hr gas by 125 stack KVA) D.G. Set 40 Flue 3 (Stand- 11 Lit/Hour - LDO/FO Gas 20 By 500 Diesel stack KVA) Lit/Hour - ii Process gas i.e. Type of pollutant gases (SO2, HCl, NH3, Cl2, NOx etc.) (Existing and Proposed) - Stack/ NAAQS (National Sr. Source of Type of Vent APCM Ambient Air Quality no. emission emission Height Standards) (meter) SO – 40 mg/Nm3 Water 2 Process NO -25 mg/Nm3 Scrubber x 1 Incinerator gas 30.0 HCl -20 mg/Nm3 / Alkali emission Chlorine-9 mg/Nm3 Scrubber Ammonia -175 mg/Nm3 - v Fugitive emission details with its mitigation measures. (Existing and Proposed) F Hazardous waste (as per the Hazardous and Other Wastes (Management and Transboundary Movement) Rules 2016. (Existing and Proposed) i Source of Categor Quantity generatio y and Type of Sr. n Schedul waste Propose Disposal No. e as per Existing Total with HW d Rules. Collection, Spent Storage, Manufact Catalys Transportatio 1. uring 28.2 0.35 3.65 4 t/Spent n and Process Carbon Disposal at TSDF site Collection, Storage, Manufact Transportatio Incinera 2. uring 37.2 1.25 10.75 12 n and tor Process Disposal at TSDF site SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 5 of 10 Collection, Storage, Distillati Manufact Transportatio on 3. uring 20.3 1.0 11 12 n and Residu Process Disposal at e CHWIF site Collection, Storage, Transportatio ETP 4. ETP Plant 35.3 1.0 11 12 n and Sludge Disposal at TSDF site Manufact Supply to Spent uring 5. 28.6 0 48 48 V.R.Chemica Solvent Process l Collection, Manufact Storage, MEE uring Transportatio 6. 35.3 0 8.4 8.4 Salt Process n and Disposal at TSDF site Manufact Sold to Waste uring 100 7. 5.1 100 200 authorized Oil L/Year Process vendors Collection, Storage, Material 200 Empty Transportatio 8. 33.3 Nos/Ye 0.6 MT 0.6 MT Bags handling n and ar Disposal at TSDF site Barrels/ Material 200 Sold to 9. Contain handling 33.3 Nos/Ye 12 MT 12 MT authorized er ar vendors Quantity of discarded containers must be in MT/Annum. ii Membership details of CETP, TSDF, CHWIF, MEE Common MEE etc. ii Details of Non-Hazardous waste & its disposal - (MSW and others) G Solvent management (If any) i Details of Solvent recovery (As per respective ToR) Disposal at co-processing or registered recycler , CHWIF ii VOC emission sources and its mitigation measures -- 9. Details of Environmental Consultants: Sr. Particulars Details no. i Name of the Consultant M/s. Excel Enviro Tech ii Validity of Certificate of accreditation Till 27/06/2018 SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 6 of 10 issued by the NABET, QCI iii Accreditation for the categories B iv Any other details - Name & designation of the Applicant: Mr. Premchand S. Patil Stamp & Signature of the Applicant: Date: 14/02/2018 General Instructions Format shall be in WORD Format (Page size-A4, Font type- Arial, Font size- 11) Provide authenticated (with stamp & Signature) hard copy during presentation. Kindly mail to : [email protected] and copy to all members. Above data should be as per application Form-1 & PFR. Incorporate relevant details in respective column of the above format. Do not attachas Annexure in Format. SEAC, Gujarat [TOR – Expansion Case] SEAC, Gujarat: Page 7 of 10 Annexure-I Product Details Quantity End-use Name of the CAS Sr. no. MT/Month of Products no. Existing Proposed Total product Beclomethasone Health 1. - 25 0 25 Dipropionate Care Betamethasone Health 2. - 50 0 50 Diropionate Care Health 3. Betamethasone I.P. - 5 0 5 Care Betamethasone Health 4. - 50 0 50 Sodium Phosphate Care Betamethasone Health 5. - 50 0 50 Valerate Care Clobetasone Health 6. - 40 0 40 Propionate Care Health 7. Clobetasone Butyrate - 10 0 10 Care Dexamethasone and Health 8. - 50 0 50 Sodium Phosphate Care Fluticasone Health 9. - 15 0 15 Propionate Care Health 10. Hydrocortisone - 20 0 20 Care Hydrocortisone Health 11. - 20 0 20 Acetate Care Health 12. Mometasone Furoate - 20 0 20 Care Health 13. Prednisolone Acetate - 25 0 25 Care Prednisolone Sodium Health 14.
Load more

Recommended publications
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer
    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]